Evidence map›Paper›PMID 39893513›Full record

ArticlePharmaceutical biology2025

Sustainable cultivation of phytopharmaceuticals in Baden-Wuerttemberg, Germany: a SWOT analysis and future directions.

Peter W Heger, Ilka Meinert, Peter Nick, Peter Riedl, Michael Heinrich, Michael Straub

Abstract read
In one paragraph

Article in Pharmaceutical biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Peter W HegerHealth Research Services GmbH, Germany.
Ilka MeinertHealth Research Services GmbH, Germany.
Peter NickKarlsruher Institut für Technologie, Joseph Gottlieb Koelreuter Institut für Pflanzenwissenschaften, Karlsruhe, Germany.
Peter RiedlSalus Haus Dr. med. Otto Greither Nachf. GmbH & Co. KG, Bruckmuehl, Germany.
Michael HeinrichPharmacognosy and Phytotherapy, University College London - School of Pharmacy, London, United Kingdom.
Michael StraubSTRAUB INT. ECO-CONSULTING, Mutlangen, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThe aim of this systematic work is a Strengths, Weaknesses, Opportunities, Threats (SWOT) analysis to select suitable medicinal plants for cultivation in the region of Baden-Wuerttemberg, Germany.

methodsA systematic SWOT analysis, based on expert assesments and literature research, was performed considering factors like market demand, cultivation conditions, and potential economic benefits.

resultsMedicinal plants have been essential for producing compounds with significant health benefits. However, unsuitable harvesting practices threaten plant species and traditional communities due to loss of knowledge and culture. In response, sustainable cultivation is gaining attention as alternative to wild collection, ensuring both biodiversity conversation and integrity of medicinal products. Three plants -

conclusionsThis publication emphasizes the importance of comprehensive planning and analysis in transitioning from wild collection to sustainable cultivation of medicinal plants, highlighting the potential benefits for regional agriculture, conservation efforts, and the pharmaceutical industry. BIOPRO Baden-Württemberg GmbH promotes this approach by fostering a bioeconomy centred on cultivating high-value medicinal plants in the state of Baden-Wuerttemberg, Germany.

Indexed as

AgricultureConservation of Natural ResourcesPlants, MedicinalArnicaBiodiversityGermanyHumansRheumArnica montana L. (true arnica;)hydrastis canadensis L. (goldenseal/canadian turmeric;)medicinal plant cultivationrheum rhaponticum L. (Rhapontic rhubarb;)sustainable cultivationSWOT analysistraditional medicine

Identifiers

PMID39893513
PMCPMC11789216

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.